Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial
Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…Distinct memory networks in Parkinson’s disease (PD) and Alzheimer’s disease (AD): Effects of APOE
Objective: As part of the Ontario Neurodegenerative Disease Research Initiative, we investigated group differences in functional connectivity within two distinct memory networks: posterior medial network…Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges
Objective: To evaluate anti-dementia properties of the selected herbal anti-inflammatory remedies Background: Parkinson’s disease (PD) is the most common age-related neurodegenerative disease after Alzheimer’s disease.…The Neuropsychiatric Inventory:Assessment Of Neuropsychiatric Symptoms In Parkinson’s Disease
Objective: We investigated the correlation of Neuropsychiatric Inventory(NPI) test score with progression of PD. Background: PD has characteristic motor symptoms and non-motor symptoms including psychiatric…Parkinsonism in a patient with limbic-predominant age-related TDP-43 encephalopathy (LATE) syndrome
Objective: To illustrate a case of parkinsonism in a patient with LATE syndrome. Background: LATE syndrome is an emerging subclassification of TDP-43 proteinopathy. Symptoms include…Progressive Gait Disturbance presumed to be caused by idiopathic peripheral neuropathy: A case of Normal Pressure hydrocephalus.
Objective: Discuss the importance of gait phenomenology in identifying Normal Pressure Hydrocephalus. Background: Normal pressure hydrocephalus (iNPH) can present as a ‘magnetic gait’ but this…Sex-Specific APOE ε4 Association with Cognition in Lewy Body Dementia
Objective: To evaluate whether association between apolipoprotein E ε4 (APOE ε4) and cognition differ for men and women with pathologically-confirmed Lewy body dementia (LBD). Background:…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…Association between Alzheimer’s disease co-pathology and neuropsychiatric symptoms in Lewy body dementia
Objective: To identify the associations between Alzheimer Disease (AD) co-pathology and neuropsychiatric symptoms in Lewy body dementia (LBD). Background: Dementia with Lewy Bodies (DLB) and…Rapidly progressive dementia after MRI-guided Focused Ultrasound (MR-FUS)
Objective: To present a Parkinson´s Disease (PD) patient who presented a rapidly progressive dementia after MR-FUS therapy. Background: MR-FUS thalamotomy is used for unilateral essential…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 36
- Next Page »